US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.51 against a street estimate of 0.31 — a beat of 64.5%.
Analysts rate Takeda Pharmaceutical Co Ltd ADR a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $23.02.
| Fund | Stake |
|---|---|
| Capital Research Global Investors | 0.60% |
| FMR Inc | 0.30% |
| Morgan Stanley - Brokerage Accounts | 0.22% |
| Adage Capital Partners Gp LLC | 0.19% |
| The Goldman Sachs Group Inc | 0.16% |
| Brandes Investment Partners & Co | 0.14% |
| Arrowstreet Capital Limited Partnership | 0.12% |
| BlackRock Inc | 0.12% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Takeda’s six months ended September 30, 2026 revenue was JPY 2,406,997 million, up 8.4% year over year at actual exchange rates (A | 2026-10-29 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • FY2026 H1 revenue was JPY 2,407.0 billion, up 8.4% year on year at actual exchange rates but down 1.0% at constant exchange rates | 2026-10-29 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • The U.S. FDA accepted Takeda’s New Drug Application (NDA) for zasocitinib (TAK-279) under Priority Review for adults with moderate | 2026-09-14 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Takeda received U.S. FDA approval on August 28, 2026, for MIMRYLO™ (rusfertide) to treat erythrocytosis in adults with polycythemi | 2026-08-31 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • The U.S. FDA approved ORZEYFUL™ (oveporexton) for treating narcolepsy type 1 (NT1) in adults. • NT1 affects an estimated 120,000 | 2026-08-06 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • FY2026 Q1 reported revenue was JPY 1,219.9 billion, up 10.2% year over year at actual exchange rates but down 0.5% at constant exc | 2026-07-30 |
| Annual report FY2026 (20-F) HEADLINE NUMBERS • The document is Takeda Pharmaceutical Company Limited’s Form 20-F annual report for the fiscal year ended March 31, 2026, filed Ju | 2026-06-17 |
| Annual report FY2025 (20-F) | 2025-06-25 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.40 / share ex-date Sep 29, 2026 | 2026-09-29 |
| Dividend | $0.31 / share ex-date Mar 31, 2026 · pay Jul 6, 2026 | 2026-03-31 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Takeda Pharmaceutical Co Ltd ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.